Brea, United States
Rapid Nexus is a clinical stage medtech company that has developed Hemastyl®, a novel peripheral neuropathy tissue healing product. This innovative solution utilizes nanomaterials to effectively eliminate infections, while rapidly increasing tissue volume and density, thus preventing limb amputations and reducing healthcare costs.
Neuropathy, which is the underlying cause of non-healing wounds, particularly in patients with diabetes, leads to skin and muscle degeneration, often resulting in necrosis. Hemastyl® has demonstrated unprecedented closure rates averaging 95.5% across 22 high-risk wounds in patient studies, even for those initially designated for amputation. This positions it as the sole technology capable of addressing this urgent global medical need, for which there is currently no other solution.
Besides its groundbreaking product, Rapid Nexus has also secured a total of 7 issued U.S. patents and 6 issued international patents. Additionally, the company has been recognized with the FAA's Tech Connect Defense Innovation Award and has partnered with the Joseph M. Still Research Foundation.
Founded in 2020 and headquartered in the United States, Rapid Nexus operates at the intersection of Biotechnology, Health Care, and Manufacturing. While the details of its last investment and investors are not available currently, the company's innovative approach and promising results make it an intriguing potential investment opportunity for venture capital firms seeking to support groundbreaking medtech solutions.
